2. Search Result
Search Result
Results for "

SOD2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

2

Recombinant Proteins

9

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134476
    NF-κΒ activator 1
    Maximum Cited Publications
    13 Publications Verification

    		 NF-κB Inflammation/Immunology
    NF-κΒ activator 1 (compound 32) is a potent NF-κΒ activator with an EC50 of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD)2 mRNA expression .
    NF-κΒ activator 1
  • HY-134477
    NF-κΒ activator 2
    5 Publications Verification

    		 NF-κB Neurological Disease
    NF-κΒ activator 2 is a potent and orally active NF- B activator, with an EC50 of 1.58 μM. NF-κΒ activator 2 induces SOD2 through increasing NF- B expression and activation. NF-κΒ activator 2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
    NF-κΒ activator 2
  • HY-W014940
    Ethylene glycol dimethacrylate

    		Reactive Oxygen Species (ROS) Apoptosis Glutathione Peroxidase SOD Others
    Ethylene glycol dimethacrylate is a diester formed by the condensation of Ethylene glycol (HY-Y0338) and Methacrylic acid. Ethylene glycol dimethacrylate is a cross-linking agent for polymers. Ethylene glycol dimethacrylate increases Apoptosis, GPx4, SOD2, ROS. Ethylene glycol dimethacrylate is cytotoxic and genotoxic. Ethylene glycol dimethacrylate exhibits cross-linking activity, enhancing the mechanical properties and stability of materials [2] .
    Ethylene glycol dimethacrylate
  • HY-158162
    SIRT3 activator 1
    1 Publications Verification

    		 Sirtuin Cardiovascular Disease
    SIRT3 activator 1 (Compound 5v) is a SIRT3 activator. SIRT3 activator 1 selectively elevates SIRT3 expression, leading to the upregulation of SOD2 and OPA1 expression, effectively preventing mitochondrial dysfunction, mitigating oxidative stress, and preserving cardiomyocyte viability. SIRT3 activator 1 can be used for research of cardiovascular diseases .
    SIRT3 activator 1
  • HY-W073128
    Perfluorotetradecanoic acid

    PFTeDA

    		 PPAR Apoptosis PGC-1α AMPK Akt mTOR Reactive Oxygen Species (ROS) Endocrinology
    Perfluorotetradecanoic acid (PFTeDA) is an orally active perfluoroalkyl substance. Perfluorotetradecanoic acid directly binds to the ligand-binding domain of purified hPPARγ, with a Kd value of 157.8 μM. Perfluorotetradecanoic acid significantly reduces the activity of the SIRT1/PGC1α and AMPK signaling pathways while stimulating the activity of the AKT1/mTOR signaling pathway. Perfluorotetradecanoic acid significantly upregulates the expression of corticosterone biosynthesis genes. Perfluorotetradecanoic acid increases ROS levels and promotes Apoptosis. Perfluorotetradecanoic acid impairs Leydig cell function and male reproductive endocrine function in adult male rats [2].
    Perfluorotetradecanoic acid
  • HY-175352
    Nurr1 agonist 14

    		Nuclear Hormone Receptor 4A/NR4A SOD IAP Survivin Calcium Channel Neurological Disease
    Nurr1 agonist 14 (Compound 32) is a Nurr1 agonist with an EC50 of 0.09  μM for Nurr1. Nurr1 agonist 14 has significant neuroprotective activity with no influence of residual DHODH inhibition. Nurr1 agonist 14 upregulates neuroprotective genes including SOD2, SESN3, BIRC5, XIAP, FLRT2 and CRMP4 in dopaminergic neurons. Nurr1 agonist 14 can be used for neurodegenerative diseases such as Alzheimer′s disease (AD), Parkinson′s disease (PD) and multiple sclerosis (MS) research .
    Nurr1 agonist 14
  • HY-N7700A
    Guluronic acid sodium
    1 Publications Verification

    G2013 SODium

    		 VEGFR Toll-like Receptor (TLR) COX NO Synthase NF-κB MMP Inflammation/Immunology Cancer
    Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases [2] .
    Guluronic acid sodium
  • HY-N7700
    Guluronic acid

    G2013

    		 MMP COX VEGFR Toll-like Receptor (TLR) NF-κB NO Synthase Inflammation/Immunology Cancer
    Guluronic acid (G2013) is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases [2] .
    Guluronic acid
  • HY-RS13560
    SOD2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SOD2 Human Pre-designed siRNA Set A contains three designed siRNAs for SOD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SOD2 Human Pre-designed siRNA Set A
    SOD2 Human Pre-designed siRNA Set A
  • HY-RS23382
    Sod2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sod2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sod2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sod2 Rat Pre-designed siRNA Set A
    Sod2 Rat Pre-designed siRNA Set A
  • HY-RS16939
    Sod2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sod2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sod2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sod2 Mouse Pre-designed siRNA Set A
    Sod2 Mouse Pre-designed siRNA Set A
  • HY-182446
    SRI-22818

    		NF-κB SOD Neurological Disease
    SRI-22818 is a NF-κB activator with an EC50 of 0.5 μM. SRI-22818 upregulates the expression of NF-κB and promotes its activation. SRI-22818 increases the level of SOD2. SRI-22818 exhibits activity in the SOD1 G93A model of amyotrophic lateral sclerosis (ALS). SRI-22818 can be used for research related to amyotrophic lateral sclerosis .
    SRI-22818
  • HY-179151
    CDK4/6-IN-26

    		CDK Reactive Oxygen Species (ROS) SOD Cancer
    CDK4/6-IN-26 is a carbamate derivative that targets CDK4/CDK6. CDK4/6-IN-26 reduces CDK4/CDK6 levels, resulting in cell cycle arrest in the G0/G1 phase and in the S phase. CDK4/6-IN-26 exhibits high potency against SW480 cells (IC50 = 6.3 μM). CDK4/6-IN-26 affects ROS levels by increasing the expression of SOD2/MnSOD. CDK4/6-IN-26 establishes several interactions with the amino acids of the CDK6 active site. CDK4/6-IN-26 can be used for the research of colorectal cancer .
    CDK4/6-IN-26
  • HY-181588
    NR4A agonist-2

    		Nuclear Hormone Receptor 4A/NR4A Neurological Disease Inflammation/Immunology
    NR4A agonist-2 is a selective pan-NR4A agonist designed based on Vidofludimus (HY-14908), with a Kd of 0.10 μM against NR4A1, and EC50 values of 0.098 μM, 0.092 μM and 0.09 μM against Nur77, Nurr1, NOR-1, respectively. NR4A agonist-2 exhibits 47-fold selectivity over DHODH, and shows no cytotoxic activity at concentrations up to 10 μM. By binding to a specific surface pocket in the ligand-binding domain of Nurr1, NR4A agonist-2 inhibits the formation of Nurr1 homodimers, activates response elements such as NBRE, NurRE, DR5, and then potently induces the expression of neuroprotective genes including BDNF, SOD2, thereby exerting neuroprotective activity. NR4A agonist-2 can be used in the research of neurodegenerative diseases such as Parkinson's disease, dementia and multiple sclerosis .
    NR4A agonist-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: